SLC2A1 and gastric cancer: showed that SLC2A1 can inhibit CD8+ T cells and B cells, which can improve the survival rate of patients with gastric cancer, and found that the upregulation of SLC2A1 has a statistically significant difference in DFS/DSS [39].